Stockholm, Sweden

Ujjwal Neogi

This inventor holds 1 USPTO granted patent. Top assignee: University of Missouri. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ujjwal Neogi: Innovator in HIV Research

Introduction

Ujjwal Neogi is a prominent inventor based in Stockholm, Sweden. He has made significant contributions to the field of biomedical research, particularly in the area of HIV treatment. His innovative work has led to the development of valuable patents that aim to combat this global health issue.

Latest Patents

Ujjwal Neogi holds a patent for "Peptide Inhibitors for the Inhibition of HIV Capsid." This patent represents a crucial advancement in the search for effective treatments against HIV, showcasing his commitment to improving health outcomes for individuals affected by the virus. He has 1 patent to his name, reflecting his focused efforts in this specialized area of research.

Career Highlights

Neogi is affiliated with the University of Missouri, where he continues to engage in groundbreaking research. His academic background and professional experience have equipped him with the skills necessary to contribute meaningfully to the scientific community. His work is characterized by a dedication to innovation and a desire to make a positive impact on public health.

Collaborations

Ujjwal Neogi has collaborated with notable researchers such as Anders Sonnerborg and Kamlendra Singh. These partnerships have enhanced his research capabilities and have fostered an environment of shared knowledge and expertise in the fight against HIV.

Conclusion

Ujjwal Neogi's contributions to HIV research through his patent and collaborations highlight his role as an important figure in the scientific community. His work not only advances our understanding of HIV but also paves the way for future innovations in treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…